Genmab A/S (GNMSF)

290,38 +9,36 (+3,33%) Börsenschluss: 03:53PM EDT

Genmab A/S

Carl Jacobsens Vej 30
Valby
Copenhagen 2500
Denmark
45 70 20 27 28
https://www.genmab.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 2.204

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Jan G.J. van de Winkel Ph.D.	Co-Founder, President & CEO	2,86M	N/A	1961
Mr. Anthony Pagano	Executive VP & CFO	1,02M	N/A	1978
Ms. Birgitte Stephensen M.Sc.	Executive VP & Chief Legal Officer	629,16k	N/A	1961
Dr. Martine J. van Vugt Ph.D.	Executive VP & Chief Strategy Officer	686,35k	N/A	1971
Mr. Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	114,39k	N/A	1976
Dr. Tahamtan Ahmadi	Executive VP, Chief Medical Officer & Head of Experimental Medicines	1,1M	N/A	1973
Dr. Mijke Zachariasse Ph.D.	Senior Director, Head of Antibody Research Materials & Non-Independent Director	157,29k	N/A	1974
Mr. Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	114,39k	N/A	1975
Mr. Anthony Mancini	Executive VP & COO	1,09M	N/A	1971
Mr. Andrew Carlsen	Senior Director, VP & Head of Investor Relations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Corporate Governance

Genmab A/Ss ISS Governance QualityScore, Stand 1. April 2024, lautet 3. Die grundlegenden Scores sind Audit: 1, Vorstand: 1, Shareholderrechte: 1, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.